Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 47Dermatologic 35Head & Neck 22Genitourinary 17Gastrointestinal 16Gynecologic 13Breast 10Lymphoid 8Sarcoma 7CNS 6Tumor-Agnostic 5Other solid neoplasm 5Endocrine 5Plasma cell 3Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasm Metastasis 4Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
cemiplimab × Tumor-Agnostic × 1 year × Clear all
NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa

Phase 1 Recruiting
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06790602 2026-04-09

SWITCH

University of California, San Diego

Phase 2 Recruiting
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07346196 2026-01-20

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

University of Chicago

Phase 2 Not yet recruiting
90 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT05259709 2025-09-11

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Regeneron Pharmaceuticals

Phase 1 Recruiting
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03871348 2025-09-10

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Terminated
77 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡